<code id='0E20AD565B'></code><style id='0E20AD565B'></style>
    • <acronym id='0E20AD565B'></acronym>
      <center id='0E20AD565B'><center id='0E20AD565B'><tfoot id='0E20AD565B'></tfoot></center><abbr id='0E20AD565B'><dir id='0E20AD565B'><tfoot id='0E20AD565B'></tfoot><noframes id='0E20AD565B'>

    • <optgroup id='0E20AD565B'><strike id='0E20AD565B'><sup id='0E20AD565B'></sup></strike><code id='0E20AD565B'></code></optgroup>
        1. <b id='0E20AD565B'><label id='0E20AD565B'><select id='0E20AD565B'><dt id='0E20AD565B'><span id='0E20AD565B'></span></dt></select></label></b><u id='0E20AD565B'></u>
          <i id='0E20AD565B'><strike id='0E20AD565B'><tt id='0E20AD565B'><pre id='0E20AD565B'></pre></tt></strike></i>

          explore

          explore

          author:entertainment    Page View:589
          A sign of AdventHealth on its building in Orlando, Florida — coverage from STAT
          Adobe

          A lawsuit between a large hospital system and a dominant vendor that works for health insurance companies is getting a lot more heated — with one party calling the other an “economic parasite.”

          The suit, between nonprofit hospital giant AdventHealth and MultiPlan, is now even attracting rare interest from the nation’s biggest hospital lobbyists.

          advertisement

          The new, highly detailed legal filings also come right as MultiPlan and more than a dozen of the largest tax-exempt, nonprofit hospital systems are wooing investors at the J.P. Morgan Healthcare Conference. AdventHealth did not attend this year’s conference, but did so last year.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          For one rare type of lung cancer, Pfizer pill reduces progression by 81%
          For one rare type of lung cancer, Pfizer pill reduces progression by 81%

          AP/BusinessWireTherearealotofreasonswhyupdateddataonPfizer’sLorbrena,atreatmentfornon-smallcelllungc

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Readout LOUD podcast: ASCO preview, a Duchenne trial failure

          WhichpresentationsareworthcatchingatASCOthisweekend?Whatisexon-skipping?Andhowdoyoupronouncebronchie